SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.
SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.
复制标题
用于细胞凋亡分子成像的 SPECT 和 PET 放射性药物：从实验室到临床
DOI：
10.18632/oncotarget.14730
复制
发表时间：
2017-03-21
期刊：
影响因子：
--
通讯作者：
Zeng W
中科院分区：
文献类型：
--
作者：
Wang X;Feng H;Zhao S;Xu J;Wu X;Cui J;Zhang Y;Qin Y;Liu Z;Gao T;Gao Y;Zeng W
由于细胞凋亡在许多人类疾病中的中心作用以及基于细胞凋亡的治疗方法的广泛应用，细胞凋亡的分子成像在临床实践中引起了临床医生的极大兴趣，并且具有很大的前景。基于细胞凋亡的明确的生化变化，已经开发了各种各样的探针和方法用于细胞凋亡的分子成像，具有各种成像模式。在这些成像技术中，核成像（包括单光子发射计算机断层扫描和正电子发射断层扫描）由于其高特异性和灵敏度而仍然是首要的临床方法。因此，相应的放射性药物一直是一个主要的焦点，其中一些如99 mTc-Annexin V，18F-ML-10，18F-CP 18和18F-ICMT-11目前正在广泛的疾病的I/II期或II/III期临床试验中进行临床研究。本文综述了近年来在临床试验中广泛应用的放射性药物，并从放射合成、药代动力学和剂量学等方面对其在不同临床阶段的应用进行了阐述。我们还探讨了所需的独特功能，以符合理想的放射性药物在临床实践中成像细胞凋亡。特别是，这些临床工作的影响，即，细胞凋亡成像作为预测和预后标志物，早期反应指标和替代终点的角度来看，也是本次审查的亮点。
Owing to the central role of apoptosis in many human diseases and the wide-spread application of apoptosis-based therapeutics, molecular imaging of apoptosis in clinical practice is of great interest for clinicians, and holds great promises. Based on the well-defined biochemical changes for apoptosis, a rich assortment of probes and approaches have been developed for molecular imaging of apoptosis with various imaging modalities. Among these imaging techniques, nuclear imaging (including single photon emission computed tomography and positron emission tomography) remains the premier clinical method owing to their high specificity and sensitivity. Therefore, the corresponding radiopharmaceuticals have been a major focus, and some of them like 99mTc-Annexin V, 18F-ML-10, 18F-CP18, and 18F-ICMT-11 are currently under clinical investigations in Phase I/II or Phase II/III clinical trials on a wide scope of diseases. In this review, we summarize these radiopharmaceuticals that have been widely used in clinical trials and elaborate them in terms of radiosynthesis, pharmacokinetics and dosimetry, and their applications in different clinical stages. We also explore the unique features required to qualify a desirable radiopharmaceutical for imaging apoptosis in clinical practice. Particularly, a perspective of the impact of these clinical efforts, namely, apoptosis imaging as predictive and prognostic markers, early-response indicators and surrogate endpoints, is also the highlight of this review.